269. Pyogenic arthritis
20 clinical trials,   26 drugs   (DrugBank: 10 drugs),   12 drug target genes,   90 drug target pathways

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02366260
(ClinicalTrials.gov)
February 201511/2/2015An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: Gevokizumab;Drug: PlaceboMedDerm AssociatesXOMA (US) LLCRecruiting18 YearsN/ABoth5Phase 3United States
2NCT02326740
(ClinicalTrials.gov)
December 201422/12/2014An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNULLTerminated18 YearsN/ABoth9Phase 3United States;Australia;Canada
3NCT02318914
(ClinicalTrials.gov)
November 20148/12/2014A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumA 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNULLTerminated18 YearsN/ABoth15Phase 3United States;Australia;Canada
4NCT02315417
(ClinicalTrials.gov)
November 20145/12/2014An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNULLTerminated18 YearsN/ABoth16Phase 3United States
5NCT01882504
(ClinicalTrials.gov)
May 201317/6/2013Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumAn Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNULLCompleted18 YearsN/ABoth8Phase 2United States